Join to View Full Profile
1660 Spring Hill AveMobile, AL 36604
Phone+1 251-665-8000
Fax+1 251-445-8378
Dr. Alkharabsheh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Omar Alkharabsheh is a Hematologist and Medical Oncologist, specializing in blood cancers and disorders including Leukemia, Lymphoma, and Multiple Myeloma.
Education & Training
Mayo Clinic College of Medicine and ScienceFellowship, Advanced Hematology Fellowship, 2017 - 2018
McLaren Health Care/Greater Lansing/MSUFellowship, Hematology and Medical Oncology, 2014 - 2017- Hurley Medical Center/Michigan State UniversityResidency, Internal Medicine, 2011 - 2014
Jordan University of Science and Technology FOMClass of 2008
Certifications & Licensure
AL State Medical License 2018 - 2025
MN State Medical License 2016 - 2019
MI State Medical License 2011 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2021 Mar 09
- Join now to see all
Publications & Presentations
PubMed
- A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse
Blood Cancer Journal. 2025-03-10 - 2 citationsTACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians.Rawan Atallah, Nausheen Ahmed, Fathima Ayoobkhan, Md Saiful Islam Saif, Emerson Logan
Transplantation and Cellular Therapy. 2024-09-01 - Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Mu...Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed
Cancers. 2023-10-09
Press Mentions
Alabama woman asks Congress to increase funding for bone marrow transplant programMarch 24th, 2023
Professional Memberships
- Member
- Member
External Links
- University of South Alabama Healthhttps://www.usahealthsystem.com/providers/omar-alkharabsheh
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
